HFS
CPRX

Hantz Financial Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Hantz Financial Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73K Buy
2,940
+518
+21% +$12.3K ﹤0.01% 1408
2025
Q4 		$57K Buy
2,422
+1,890
+355% +$42.1K ﹤0.01% 1381
2025
Q3 		$10K Buy
532
+157
+42% +$3.23K ﹤0.01% 1825
2025
Q2 		$8K Buy
375
+372
+12,400% +$8.78K ﹤0.01% 1573
2025
Q1 		$0 Buy
+3
New +$68 ﹤0.01% 1731

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Hantz Financial Services's CPRX Position: Q1 2026 in Review

Hantz Financial Services increased its Catalyst Pharmaceutical (CPRX) stake by 21% in Q1 2026, buying an estimated $12.3K and bringing the position to 2,940 shares worth $73K. The position accounts for ﹤0.01% of the portfolio, ranked #1408.

Hantz Financial Services first reported a position in CPRX in Q1 2025 and has held it in 5 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Hantz Financial Services held 2,940 shares of Catalyst Pharmaceutical worth $73K as of Q1 2026.
  • Hantz Financial Services bought 518 Catalyst Pharmaceutical shares in Q1 2026, an estimated $12.3K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Hantz Financial Services's portfolio in Q1 2026, its #1408 holding.
  • Hantz Financial Services first reported a position in Catalyst Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Hantz Financial Services's 13F filing for Q1 2026, filed 1 May 2026.